Every Monday since 2011, the Basler Zeitung has been publishing a weekly column by Interpharma General Secretary Thomas Cueni on a subject of his own choosing. In 2016 more than 50 columns were published, most of which related to current (pharma) policy issues and also appeared in the Interpharma newsroom. With a circulation of around 49,300 and a total readership of 109,000, the Basler Zeitung ensures that these columns enjoy a considerable reach.
Columns in the Journal for Swiss SMEs (Schweizerische Gewerbezeitung)
Three guest contributions by Thomas Cueni were also published in the Schweizerische Gewerbezeitung (the journal for Swiss SMEs), which carries a column titled Tribüne, where business leaders are given a platform to express their views. In the first article Cueni discussed the importance of Corporate Tax Reform III (CTR III) not only for multinational pharmaceutical companies, but also for SMEs, and in the second article he addressed the issue of European collaboration in research. The third article dealt with CTR III again. With a circulation of more than 106,000, this journal likewise ensured that these contributions enjoyed a substantial reach.
In September, Interpharma appeared in a life sciences supplement of the Basler Zeitung with a guest article by General Secretary Thomas Cueni on the importance of the bilateral accords and an advertisement.